These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 15492826

  • 1. Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: a combined study of spectral karyotyping, positional expression profiling and candidate genes.
    Hu Y, Pang E, Lai PB, Squire JA, MacGregor PF, Beheshti B, Albert M, Leung TW, Wong N.
    Int J Oncol; 2004 Nov; 25(5):1357-64. PubMed ID: 15492826
    [Abstract] [Full Text] [Related]

  • 2. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy.
    Perugorria MJ, Castillo J, Latasa MU, Goñi S, Segura V, Sangro B, Prieto J, Avila MA, Berasain C.
    Cancer Res; 2009 Feb 15; 69(4):1358-67. PubMed ID: 19190340
    [Abstract] [Full Text] [Related]

  • 3. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.
    Pang E, Hu Y, Chan KY, Lai PB, Squire JA, Macgregor PF, Beheshti B, Albert M, Leung TW, Wong N.
    Lab Invest; 2005 May 15; 85(5):664-74. PubMed ID: 15765123
    [Abstract] [Full Text] [Related]

  • 4. Gene expressions associated with chemosensitivity in human hepatoma cells.
    Hoshida Y, Moriyama M, Otsuka M, Kato N, Taniguchi H, Shiratori Y, Seki N, Omata M.
    Hepatogastroenterology; 2007 Mar 15; 54(74):489-92. PubMed ID: 17523305
    [Abstract] [Full Text] [Related]

  • 5. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines.
    Wang J, Chan JY, Fong CC, Tzang CH, Fung KP, Yang M.
    Liver Int; 2009 Oct 15; 29(9):1338-47. PubMed ID: 19627484
    [Abstract] [Full Text] [Related]

  • 6. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
    Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, Kort E, Cole A, Resau J, Bradford C, Carey T, Wennerberg J, Anderson H, Tennvall J, Teh BT.
    Clin Cancer Res; 2004 Dec 15; 10(24):8204-13. PubMed ID: 15623595
    [Abstract] [Full Text] [Related]

  • 7. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
    Chen YB, Yan ML, Gong JP, Xia RP, Liu LX, Li N, Lu SC, Zhang JG, Zeng DB, Xie JG, Yang JY, Yan LN.
    Chin Med J (Engl); 2007 Apr 20; 120(8):703-7. PubMed ID: 17517188
    [Abstract] [Full Text] [Related]

  • 8. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest.
    Gho JW, Ip WK, Chan KY, Law PT, Lai PB, Wong N.
    Cancer Res; 2008 Aug 15; 68(16):6743-51. PubMed ID: 18701499
    [Abstract] [Full Text] [Related]

  • 9. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
    Tsang WP, Kwok TT.
    Oncogene; 2007 Jul 19; 26(33):4877-81. PubMed ID: 17297456
    [Abstract] [Full Text] [Related]

  • 10. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM.
    Breast Cancer Res Treat; 2006 Mar 19; 96(1):17-39. PubMed ID: 16322897
    [Abstract] [Full Text] [Related]

  • 11. A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.
    Wong N, Lai P, Pang E, Leung TW, Lau JW, Johnson PJ.
    Hepatology; 2000 Nov 19; 32(5):1060-8. PubMed ID: 11050057
    [Abstract] [Full Text] [Related]

  • 12. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM, El-Awady RA, Abdel Alim MA, Abdel Wahab AH.
    Cell Biochem Biophys; 2009 Nov 19; 55(2):95-105. PubMed ID: 19593673
    [Abstract] [Full Text] [Related]

  • 13. Loss of expression of Kruppel-like factor 6 in primary hepatocellular carcinoma and hepatoma cell lines.
    Wang SP, Zhou HJ, Chen XP, Ren GY, Ruan XX, Zhang Y, Zhang RL, Chen J.
    J Exp Clin Cancer Res; 2007 Mar 19; 26(1):117-24. PubMed ID: 17550140
    [Abstract] [Full Text] [Related]

  • 14. Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma.
    Ip WK, Lai PB, Wong NL, Sy SM, Beheshti B, Squire JA, Wong N.
    Cancer Lett; 2007 Jun 08; 250(2):284-91. PubMed ID: 17126992
    [Abstract] [Full Text] [Related]

  • 15. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma.
    Shiraki K, Yamanaka T, Inoue H, Kawakita T, Enokimura N, Okano H, Sugimoto K, Murata K, Nakano T.
    Int J Oncol; 2005 May 08; 26(5):1273-81. PubMed ID: 15809718
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
    Chan KT, Lung ML.
    Cancer Chemother Pharmacol; 2004 Jun 08; 53(6):519-26. PubMed ID: 15004724
    [Abstract] [Full Text] [Related]

  • 19. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma.
    Lu CY, Hsieh SY, Lu YJ, Wu CS, Chen LC, Lo SJ, Wu CT, Chou MY, Huang TH, Chang YS.
    Genes Chromosomes Cancer; 2009 Dec 08; 48(12):1057-68. PubMed ID: 19760608
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.